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ABSTRACT
Objective Hepatitis C virus (HCV) infection is common. 
Although treatment is effective, with oral antivirals curing 
>95% of patients, most individuals have comorbidities 
that persist long term. Therefore, our aim was to 
determine the prevalence of potentially modifiable health 
problems in patients with HCV and develop an HCV care 
bundle to identify and target comorbidities.
Design Cross- sectional, observational single- centre study 
that recruited consecutive patients with HCV from our viral 
hepatitis clinics. Data were collected on cardiovascular 
(CV) risk factors, lifestyle behaviours, anthropometry and 
health- related quality of life (HRQoL). QRISK 3 was used to 
predict 10- year CV event risk.
Results 100 patients were recruited (67% male, 93% 
white, median age 52 years (range 24–80); 71% were 
treated for HCV; 34% had cirrhosis; 14% had diabetes; 
61% had hypertension; 31% had metabolic syndrome; 
and 54% were smokers). The median 10- year CV event 
risk was 8.3% (range 0.3%–63%). 45% had a predicted 
10- year CV event risk of >10%. Only 10% of individuals 
were treated with statins and 27% with antihypertensives. 
92% had a predicted ‘heart age’ greater than their 
chronological age (median difference +7 (−4 to +26) 
years). HRQoL was reduced in all SF36v2 domains in the 
cohort. Factors independently associated with HRQoL 
included cirrhosis, metabolic syndrome, history of mental 
health disorder, sedentary behaviour and HCV viraemia.
Conclusion A large proportion of patients with HCV 
presented with increased risk of CV events, and rates 
of smoking and sedentary behaviour were high, while 
prescribing of primary prophylaxis was infrequent. HRQoL 
was also reduced in the cohort. A ‘care bundle’ was 
developed to provide a structured approach to treating 
potentially modifiable health problems.
INTRODUCTION
Hepatitis C virus (HCV) infection is common, 
affecting an estimated 71 million people 
worldwide.1 In England, latest estimates 
suggest there are 113 000 individuals chron-
ically infected with HCV, with injecting drug 
use (IDU) accounting for 85% of infections.2 
Chronic HCV infection causes persistent 
hepatic inflammation that progresses to 
cirrhosis in 10%–20% of infected individ-
uals after 20–30 years.3 4 The development of 
cirrhosis is associated with a significant risk of 
developing liver failure, hepatocellular carci-
noma and the potential requirement for liver 
transplantation.3 5
Summary box
What is already known about this subject?
 ► Patients with hepatitis C virus (HCV) frequently have 
comorbidities that persist despite successful anti-
viral therapy, and this is associated with reduced 
health- related quality of life (HRQoL). HCV is also an 
independent risk factor for type 2 diabetes mellitus 
(T2DM) and cardiovascular (CV) disease.
What are the new findings?
 ► We found that our cohort of patients with HCV were 
at high risk of CV events, with 92% having a higher 
risk than expected for someone of their age using 
QRISK3.
 ► Despite the cohort having high rates of smoking, 
hypertension, obesity, dyslipidaemia and T2DM, few 
patients had these risk factors treated.
 ► HRQoL was reduced in all domains of the SF36v2 in 
this cohort of patients with HCV.
 ► Factors independently associated with HRQoL in-
cluded cirrhosis, metabolic syndrome, history of 
mental health disorder, sedentary behaviour and 
HCV viraemia.
How might it impact on clinical practice in the 
foreseeable future?
 ► This work has highlighted the need to assess and 
treat CV risk factors in individuals with HCV.
 ► Our findings suggest that engaging sedentary in-
dividuals with HCV in a physical activity/exercise 
programme may improve their general health and 
well- being.
 ► A ‘care bundle’ was developed to help clinicians ac-
tively look for and treat potentially modifiable health 
problems, including CV disease, depression, alcohol 
consumption and substance misuse.
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There has been substantial progress in the treatment 
of HCV and now >95% of patients treated with an oral 
combination of direct acting antivirals (DAAs) for 8–12 
weeks achieve sustained virological response (SVR=cure 
of the infection).6 Given the wide availability of DAAs, 
there is an unprecedented opportunity to eliminate 
this infection worldwide.7 8 Despite progress in anti-
viral therapy, up to 40% of infected individuals remain 
undiagnosed, and a large proportion of those previ-
ously diagnosed are lost to follow- up.2 9 In order to work 
towards HCV elimination, viral hepatitis teams have had 
to invest significant resources on case finding and have 
streamlined treatment pathways with far fewer clinical 
contacts in order to upscale treatment rates. Previously, 
when patients received interferon- based treatment, they 
were provided with regular holistic care, addressing all of 
their health needs. As a result of the streamlining of care 
pathways with DAAs, care of patients with HCV may have 
become less holistic, reducing opportunities to address 
non- HCV- related health needs.
Following successful antiviral therapy for HCV, almost 
all patients (99%) have at least one comorbidity that 
persists long term.10 This includes neuropsychiatric 
conditions, such as depression, anxiety and mood disor-
ders.11 HCV is also an independent risk factor for type 
2 diabetes mellitus (T2DM) and cardiovascular (CV) 
disease, and as a result is associated with an increased risk 
of early CV- related mortality and all- cause mortality.12–14 
Successful treatment of HCV may reduce future risk 
of CV events and the development of T2DM,15 16 but 
even individuals with treated HCV remain at risk of CV 
complications.17 Health- related quality of life (HRQoL) 
is also reduced in patients with HCV compared with the 
general population.18 Treatment of HCV may lead to 
sustained improvement in HRQoL, but impaired HRQoL 
frequently persists despite HCV treatment due to associ-
ated comorbidities.19 20
The aim of this study was to assess a cohort of patients 
with HCV to determine the burden of other health prob-
lems that could be targeted to improve their health and 
well- being and ultimately to improve care pathways for 
these individuals by addressing their other health needs. 
Specifically, we aimed to
1. Characterise the cardiometabolic risk status in individ-
uals with HCV and to identify modifiable factors that 
can be targeted for improvement.
2. Characterise HRQoL status in individuals with HCV 
and identify modifiable factors that could be targeted 
for improvement.
3. Develop a simple ‘care bundle’ for individuals with 
HCV to help their treating teams recognise and ad-
dress some of their other important health needs 
during their HCV treatment.
METHODS
Study design
This was a cross- sectional, observational study that 
recruited 100 consecutive patients with HCV (treated 
or untreated) attending viral hepatitis clinics at The 
Newcastle upon Tyne Hospitals NHS Foundation Trust.
Patients
Patients over the age of 18 years were included if they had 
chronic HCV infection (defined as HCV RNA detectable 
in blood for >6 months) or had achieved SVR (3 months 
post- treatment) following treatment for chronic HCV 
infection. Patients were excluded if they were currently 
on antiviral treatment for HCV or within 3 months post- 
treatment, were coinfected with hepatitis B or HIV, had a 
history of hepatocellular carcinoma, had a history of liver 
transplantation; had decompensated cirrhosis (Child–
Pugh Score≥7), or were unable to give informed consent.
Outcomes
The primary outcome of the study was to identify the 
proportion of patients with one or more cardiometa-
bolic risk factors, including (1) overweight or obesity, (2) 
insulin resistance/T2DM (fasting glucose>5.6 or diag-
nosed with T2DM or glycated haemoglobin (HbA1c)>48 
mmol/mol), (3) hypertension (blood pressure>130/85 
or specific treatment for hypertension), and (4) dyslip-
idaemia—reduced high- density lipoprotein (HDL) 
(<1.03 mmol/L for men or <1.29 mmol/L for women) or 
triglycerides>1.7 mmol/L or specific treatment for lipid 
disorder.21
Secondary outcomes included (1) individuals’ 
projected 10- year risk of a CV event as defined by QRISK3, 
(2) smoking status, (3) patients’ current physical activity 
levels, (4) prevalence of harmful or hazardous alcohol 
use, and (5) HRQoL as assessed by the Hepatitis Quality 
of Life Questionnaire (HQLQv2) and factors associated 
with impaired HRQoL.
Data collection variables
Clinical and laboratory data were collected prospectively 
from the time of enrolment. Relevant clinical details, 
including gender, age, weight, height, body mass index 
(BMI) and waist circumference were obtained. Smoking 
history was documented as never smoked, current smoker 
or previous smoker (for >1 year). History of previous 
IDU was recorded as never, previous or current (within 
the last month). Blood tests were taken, including full 
blood count, urea and electrolytes, liver enzymes, HbA1c, 
lipids, glucose, vitamin D and HCV RNA using standard 
techniques. A detailed medical history, including a list of 
current prescribed medications, was recorded and cross- 
referenced with information from primary care.
Information was collected on their HCV infection 
history, including suspected route of infection, previous 
antiviral treatment and outcomes, and current status 
(active HCV viraemia or SVR). Stage of liver fibrosis 
was defined using transient elastography and catego-
rised as minimal or mild fibrosis (liver stiffness measure-
ment (LSM)<8 kPa), moderate- advanced fibrosis (LSM 
8–12.4 kPa) or cirrhosis (LSM>12.5 or liver biopsy 
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demonstrating Ishak stage V or VI fibrosis or imaging 
evidence of cirrhosis with portal hypertension).
The history of current alcohol consumption was eval-
uated by documenting individuals’ reported current 
average alcohol consumption in UK units/week over the 
previous year. Previous ‘heavy’ alcohol consumption was 
defined as >30units/week for women or >50 units/week 
for men for >1 year. The Alcohol Use Disorders Identifi-
cation Test (AUDIT) questionnaire was also completed 
by each individual.22 An AUDIT score of ≥8 indicates an 
increased risk of hazardous/harmful alcohol consump-
tion; ≥15 indicates high risk of hazardous/harmful 
alcohol consumption; and ≥20 indicates possible alcohol 
dependence.
Data were also collected on history of previous CV 
disease, including ischaemic heart disease, cerebrovas-
cular disease, peripheral vascular disease or atrial fibril-
lation. CV risk was determined using QRISK3 ( www. qrisk. 
org). This is a validated online tool used to estimate an 
individual’s predicted 10- year risk of having a CV event 
based on a number of readily available clinical variables, 
such as blood pressure, smoking status, presence of 
T2DM, BMI, family history, cholesterol:HDL ratio and 
history of medical conditions associated with increased 
CV risk. All information required for calculation of 
QRISK3 was collected. The QRISK3 also calculates a 
patients’ ‘healthy heart age’, which is the estimated 
age of a healthy person of the same sex and ethnicity 
with the same 10- year QRISK3. We compared patients’ 
chronological age with their estimated biological heart 
age (estimated heart age–chronological age) to give an 
assessment of their CV health compared with their peers.
Patients’ current self- reported physical activity level 
was recorded as sedentary, engaging in regular moderate 
physical activity (≥150 min/week of activity that leads to 
faster breathing, increased heart rate and feeling warmer) 
or regular vigorous physical activity (≥75 min/week of 
activity that leads to very hard breathing, shortness of 
breath, rapid heartbeat and should leave a person unable 
to maintain a conversation comfortably). Body composi-
tion was measured using 8- point Bioelectrical Impedance 
Analysis (BIA) (SECA BIA mBCA 525 Machine, SECA, 
UK).
Information on history of mental health disorders was 
also collected. We defined a ‘significant’ mental health 
disorder as one where pharmacological treatment was 
used for its treatment. HRQoL was determined using the 
HQLQv2, a survey to assess the functional health and 
well- being of patients with HCV, using a combination 
of the Short- Form 36v2 (SF36v2) Health Survey and 15 
additional questions that measure other generic heath 
concepts relevant in assessing the impact of hepatitis. 
The SF36v2 consists of a survey of questions that are used 
to construct scores for eight domains (0–100 scale) and 
from these two, summary scores reflecting physical health 
(physical health component summary (PCS) score) and 
mental health (mental health component summary 
(MCS) score) are generated. SF36v2 scores presented in 
this study for the eight domains, the PCS and MCS were 
normalised to the US general population to have a mean 
of 50 and and SD of 10.23 Therefore, SF36v2 scores below 
50 were considered reduced HRQoL. For the hepatitis- 
specific scores, the Hepatitis Distress Scale (HD), positive 
well- being (PWB), Hepatitis- specific Limitations Scale 
(HLIM) and Hepatitis- specific Health Distress Scale 
(HHD) scores ranged from 0 to 100 (not normalised to 
the US population), with higher scores indicating better 
HRQoL.
Measure of deprivation
The home postcode for each patient was mapped onto 
the English Indices of Deprivation using the Index of 
Multiple Deprivation (IMD).24 The lower layer super 
output area (LSOA) was calculated for each individual 
patient postcode. Deciles (1–10) for the IMD are calcu-
lated by ranking the 32 844 LSOAS in England from most 
deprived to least deprived and dividing into 10 equal 
groups (1 being the most deprived area decile and 10 the 
least deprived).
Development of the care bundle
A care bundle was developed to address general health 
needs of patients based on the findings from this study. 
Recommendations within the bundle are based on 
National Institute of Health and Care Excellence (NICE) 
guidelines.25–30 The bundle was initially developed by 
KH, PP and SMcP and then revised in response to crit-
ical review by a panel of experts, including hepatologists, 
specialist nurses, lifestyle specialists, addiction specialists 
and patients.
Statistical analysis
All statistical analyses were performed using the SPSS soft-
ware V.24.0. Continuous normally distributed variables 
are represented as mean and ±SD. Categorical and non- 
normal variables are summarised as median and IQR. χ2 
tests were used to determine the distribution of categor-
ical variables between groups. To compare the means of 
normally distributed variables between groups, Student’s 
t- test or analysis of variance test was performed. To deter-
mine differences between groups for continuous non- 
normally distributed variables, medians were compared 
using the Mann- Whitney U- test. The strength of associa-
tion between clinical variables was assessed by Pearson or 
Spearman correlations. To identify factors independently 
associated with PCS and MCS, a backward stepwise binary 
logistic regression was conducted, including variables 
associated with the outcome on univariate analysis with a 
p value of <0.2. Backward stepwise linear regression was 
used to identify factors independently associated with the 
hepatitis- specific HRQoL scores (HD, PWB, HLIM and 
HHD), including all variables associated with a univar-
iate analysis p value of <0.2. Gender and index of depri-
vation were included in all models. A p value of <0.05 was 
considered significant.
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One hundred patients with HCV (viraemic or success-
fully treated) were recruited to this study. The patient 
characteristics are shown in table 1. Overall, two- thirds 
of the cohort was male and the majority (93%) was of 
white ethnicity. The mean age was 51±13 years (range 
24–80 years). Overall, 71% had treated HCV and 29% 
were viraemic (5% of these had failed antiviral treat-
ment). Thirty- four per cent of the cohort had cirrhosis 
(LSM>12.5 kPa) and 54% had minimal or mild liver 
fibrosis (LSM<8 kPa).
The main risk factor for HCV acquisition was IDU in 
60% of cases. Seven per cent of the cohort were regu-
larly engaging in IDU and 24% regularly engaged in 
substance misuse. The overall median alcohol consump-
tion was 0 unit/week (IQR 0–10), but this ranged up to 
280 units/week. A total of 23% of the cohort consumed 
>14 units of alcohol per week and 44% had a history of 
previous ‘heavy’ alcohol consumption (>30 units/week 
for women and >50 units/week for men for >1 year). The 
median AUDIT score was 3 (IQR 0–10) and 29% had an 
AUDIT ≥8, suggestive of increased risk of hazardous/
harmful drinking, while 7% had an AUDIT ≥20 indi-
cating possible dependence. Overall, 76% of the cohort 
were in the lower 5 deciles of the IMD (indicating higher 
deprivation) and 59% were in the lowest three deciles.
Cardiometabolic risk factors
The mean BMI was 27.9±6 kg/m2 with 28% and 38% 
of individuals classified as overweight or obese, respec-
tively. Thirty- seven per cent of patients had central 
obesity as defined by International Diabetes Federation 
waist circumference criteria.21 A total of 14% had diag-
nosed T2DM and two patients had undiagnosed T2DM. 
Sixty- one per cent had hypertension and 27% (44% of 
those with hypertension) were treated with antihyperten-
sive medications. Thirty- nine per cent had dyslipidaemia 
(reduced HDL, triglycerides>1.7 mmol/L or specific 
treatment for lipid disorder), and 10% were treated with 
lipid- lowering drugs. Thirty- one per cent of the patients 
had metabolic syndrome, and 80% had one or more 
metabolic risk factors.21 Remarkably, 79% had a history 
of smoking, and 54% were current smokers.
Fifty- nine per cent of the patients self- reported being 
sedentary, while 26% reported regular moderate phys-
ical activity and 15% regular vigorous physical activity. 
Body composition was assessed in 58 individuals using 
bioimpedance, and the median fat mass in men was 
28.7% (IQR 21.8%–33.1%) and that in women was 39% 
(IQR 26.9–41.6). Of these individuals, 65% of women 
and 58% of men had body fat levels above normal (25%+ 
for men and 32%+ for women). There were strong rela-
tionships between total fat mass and both BMI (rs=0.64, 
p=0.006 for women and rs=0.67, p<0.001 for men) and 
waist circumference (rs=0.56 p=0.02 for women and 
rs=0.71 p<0.001 for men). Overall, there was a relation-
ship between fat mass and the number of features of the 
Table 1 Overview of the clinical and demographic features 
of the cohort
Age (years) 51.3±13.1 (range 24–80)
Gender 67% male
White ethnicity 93%
HCV treatment status   
  HCV viraemia currently 29%
  Untreated 24%
  SVR 71%
  Failed antiviral treatment 5%
Substance misuse   
  Previous IDU 60%
  Current IDU 7%
  Current substance misuse 24%
Stage of fibrosis   
  Minimal or mild (LSM<8 kPa) 54%
  Moderate–advanced (8.0–12.5 kPa) 12%
  Cirrhosis (LSM>12.5 kPa) 34%
BMI (kg/m2) 27.9±6.0
  Normal (<25) 34%
  Overweight (25–29.9) 28%
  Obese (30+) 38%
Waist circumference (cm)   
  Men 96.2±13.6
  Women 94.4±16.9
  Central obesity on waist criteria 37%
Met syndrome 31%
Hypertension 61%





Current treatment for dyslipidaemia 10%
Number of Met syndrome features   
  0 20%
  1 28%
  2 21%
  3 21%
  4 8%
  5 2%
Fat mass (%)   
  Males (n=41) 28.7 (range 6.7–45.4, 
IQR 21.8–33.1)
  Females (n=17) 39.0 (range 12.4–54.5, 
IQR 26.9–41.6)
Smoking   
  Never 21%
  Previous 25%
  Current 54%
Continued
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metabolic syndrome (rs=0.37, p=0.006). There were no 
relationships between fat mass and activity levels (p>0.05).
Projected 10-year CV event risk
In total, 9% of patients had a formal diagnosis of CV 
disease. The median 10- year CV event risk estimated by 
QRISK3 was 8.2% (range 0.3%–63%, IQR 3.1–16.2). 
Overall, 45% of individuals had a predicted 10- year 
CV event risk of >10%, all of which were aged over 45 
years. Despite presenting with a CV event risk indica-
tive of statin treatment,29 only 10% of these individuals 
were treated with lipid- lowering drugs. Remarkably, 92% 
had a predicted biological ‘heart age’ greater than their 
chronological age (median difference +7 (−4 to +26) 
years). There was no significant difference between the 
predicted biological heart age and chronological age 
for individuals with treated HCV and those with active 
HCV (p=0.92). Patients with cirrhosis had a significantly 
higher median predicted 10- year CV event risk than 
patients without cirrhosis (11.1% (IQR 7.7–19.2) vs 5.3% 
(IQR 1.6–14.5), p=0.002).
Psychological comorbidity and HRQoL
This cohort had a very high prevalence of mental health 
disorders with 53% having a history of treatment for a 
mental health disorder, such as depression, anxiety or 
other psychiatric disorders. HRQoL was reduced in the 
cohort with mean scores for all domains of the SF36v2 
being below that of the general population (figure 1A). 
Table 2 shows the relationship between clinical factors 
and both the PCS and the MCS scores for the whole 
cohort. Overall, the PCS score were significantly associ-
ated with the age, presence of cirrhosis, the metabolic 
syndrome, history of a mental health disorder, regular 
physical activity level and index of deprivation. Factors 
associated with the MCS were the presence of the meta-
bolic syndrome, history of a mental health disorder, 
current smoking, IDU history, regular physical activity 
level and index of deprivation.
Following multivariate analysis (table 3) correcting for 
gender and index of deprivation, presence of cirrhosis 
and the metabolic syndrome were independently associ-
ated with reduced PCS (<50). Reduced MCS (<50) was 
independently associated with regular moderate phys-
ical activity and a history of mental health disorder after 
correcting for gender and index of deprivation (table 3). 
A comparison of the individual components of the 
SF36v2 between individuals with and without the factors 
independently associated with PCS and MCS is shown in 
figure 1B–E.
Relationship between clinical factors and hepatitis-specific 
HRQoL domains
Relationships between clinical factors and the hepatitis- 
specific HRQoL domains for the entire cohort are shown 
in online supplementary table 1. History of depression, 
current substance misuse and a sedentary lifestyle were 
associated with a lower (worse) HD score (p<0.001, 
p=0.02 and p=0.02, respectively). Achieving SVR and 
engaging in regular physical activity were associated with 
a higher PWB score (p=0.04 and p=0.01, respectively), 
whereas a diagnosis of depression was associated with a 
significantly lower score (p<0.001). Patients with viraemia 
had a significantly lower (more limitation) HLIM score 
(p=0.03). A lower (more distress) HHD score was associ-
ated with the presence of HCV viraemia and a diagnosis 
of depression (p=0.004 and p<0.001, respectively).
QRISK3   
  Risk of CV event in 10 years (%) 8.2 (range 0.3–63; IQR 
3.1–16.2)
  ‘Heart age’ 62 (range 32–83; IQR 
51–71)
  Difference between heart age and 
actual age
+7(range −4 to +26, IQR 
+4–+12)
  >10% risk of CV event in 10 years 45%
Alcohol   
  Current consumption (units week) 0 (range 0–280, IQR 
0–10)
  Current consumption >14 units/
week
23%
  Previous ‘heavy’ alcohol 
consumption
44%
  AUDIT score 3 (range 0–34, IQR 
0–10)
  <8 71%
  8–14 16%
  15–19 6%
  20+ 7%
History of mental health disorder 53%
Current regular physical activity level   
  Sedentary 59%
  Moderate activity 26%
  Vigorous activity 15%
Index of Multiple Deprivation (decile)   
  1 31
  2 10
  3 18
  4 12
  5 5
  6 5
  7 4
  8 6
  9 6
  10 3
AUDIT, Alcohol Use Disorders Identification Test; BMI, body 
mass index; CV, cardiovascular; HCV, hepatitis C virus; IDU, 
injecting drug used; LSM, liver stiffness measurement; Met, 
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To determine factors independently associated with the 
hepatitis- specific HRQoL domains, multivariable linear 
regression correcting for gender and index of depriva-
tion was performed (table 3). This identified that a seden-
tary lifestyle, the presence of a psychiatric disorder and 
current substance misuse were independently associated 
with the HD score. The PWB score was independently 
associated with a sedentary lifestyle and a history of mental 
health disorder. The presence of viraemia and current 
substance misuse were independently associated with the 
HLIM score. The HHD score was independently associ-
ated with achieving SVR, exercising more frequently and 
a diagnosis of depression. Figure 2F shows scores for the 
hepatitis- specific HRQoL domains for individuals who 
were viraemic and those who had achieved SVR.
DISCUSSION
HCV is one of the major causes of cirrhosis worldwide. 
In addition to causing hepatic complications, HCV is 
associated with extrahepatic manifestations, including 
an increased risk of T2DM, CV disease and neuropsychi-
atric conditions.11–14 The aim of this study was to assess 
a cohort of patients with HCV to determine the burden 
of health problems that could be targeted to improve 
their health and well- being, specifically cardiometabolic 
risk factors and HRQoL, and to develop a care bundle 
to improve the holistic care of these patients. One of 
the most striking findings from this study was that the 
cohort had a very high estimated CV event risk. Remark-
ably, 92% of the cohort had an estimated heart age, using 
QRISK3, greater than their chronological age. Overall, 
45% of individuals in the cohort had a predicted 10- year 
CV event risk of greater than 10%, a rate at which NICE 
guidelines recommend primary prevention with statin 
treatment.29 Unfortunately, rates of statin and anti-
hypertensive prescribing were low at 10% and 27%, 
respectively, meaning many of these individuals were not 
receiving treatments known to extend life and reduce CV 
risk. Moreover, statins may have other benefits to patients 
with HCV, including potentially slowing progression to 
cirrhosis, reducing risk of hepatic decompensation and 
reducing incidence of hepatocellular carcinoma.31 32 
This high overall CV risk in the cohort is most likely due 
to the very high rates of smoking in the cohort (54% 
current smokers vs 14% in the UK general population)33 
and the high prevalence of metabolic risk factors, with 
80% having one metabolic risk factor and 31% having 
full metabolic syndrome. HCV is well known to have 
complex interactions with glucose and lipid metabo-
lism that may impact on CV risk.34 Recent data have 
suggested that successful treatment with DAAs improves 
glycaemia and reduces incidence of T2DM.35 36 However, 
serum cholesterol and low- density lipoprotein levels may 
increase post- treatment,36 emphasising the importance 
of assessing individual CV risk. It is not clear from our 
study why rates of prescribing drugs for primary preven-
tion of CV risk were low in this cohort. This could be due 
to patient factors, such as individuals not attending for 
annual medical reviews or patients declining treatment 
with these drugs. It is also possible that some patients may 
not be offered regular CV reviews or treatment due to 
discrimination because stigma about HCV still exists in 
healthcare systems.37
Figure 1 (A) HRQoL measured using the SF36v2 for 
the cohort. (B) A comparison between SF36v2 scores for 
HRQoL between individuals with and without cirrhosis. (C) 
Comparison between SF36v2 scores for HRQoL between 
individuals with and without metabolic syndrome. (D) 
Comparison between SF36v2 scores for HRQoL between 
individuals, depending on engagement in regular moderate 
physical activity. (E) Comparison between SF36v2 scores for 
HRQoL between individuals with and without a diagnosis of 
a mental health disorder. (F) Comparison of scores for the 
hepatitis- specific domains of HRQoL between individuals 
with active viraemia and those who achieved SVR. (A–E) Data 
are displayed for the eight domains and the two composite 
summary scores (physical health component summary and 
mental health component summary). SF36v2 scores for 
the domains and summary scores were normalised to the 
US general population. Scores below 50 (horizontal black 
line) indicate reduced HRQoL. (F) These scores were non- 
normalised. Conditional differences between groups and 
were assessed by t- test (B–E) and Mann–Whitney U -test (F). 
* denotes <0.05; ** denotes <0.01 and *** denotes <0.001. 
BP, bodily pain; GH, general health; HD, Hepatitis Distress 
Scale; HHD, Hepatitis- specific Health Distress Scale; 
HLIM, Hepatitis- specific Limitations Scale; HRQoL, health- 
related quality of life; MCS, mental health component; Met 
syn, metabolic syndrome; MH, mental health; PF, physical 
functioning; PHC, physical health component; PWB, positive 
well- being; RE, role—emotional; RP, role—physical; SF36v2, 
Short- Form 36v2; SF, social functioning; SVR, sustained 
virological response; VT, vitality.
copyright.








astroenterol: first published as 10.1136/bm




7McPherson S, et al. BMJ Open Gastro 2020;7:e000470. doi:10.1136/bmjgast-2020-000470
Open access
Table 2 Relationship between PCS and MCS and clinical factors
Factor PCS P value MCS P value
Gender   0.47   0.67
  Male 44.4±11.8 39.1±15.1
  Female 42.6±11.4 40.5±14.9
Age r=−0.26 0.01 r=0.17 0.09
HCV status   0.59   0.11
  Viraemic 43.3±11.9 41.2±15.4
  SVR 44.7±11.2 35.8±13.3
Cirrhosis   0.008   0.31
  No 46.0±11.0 38.5±14.2
  Yes 39.4±11.7 41.8±16.3
BMI r=−0.18 0.08 r=0.1 0.92
Hypertension   0.7   0.49
  No 44.4±12.9 40.8±15.1
  Yes 43.5±10.7 38.6±15.2
T2DM   0.75   0.64
  No 44.0±12.0 39.5±14.9
  Yes 42.9±9.6 41.6±14.9
Metabolic syndrome   0.045   0.035
  No 45.6±12.1 42.7±14.5
  Yes 40.7±9.2 35.3±15.1
Current smoker   0.23   0.02
  No 45.1±10.9 43.1±16.2
  Yes 42.2±12.4 35.8±13.1
QRISK3 r=−0.14 0.19 r=0.06 0.59
AUDIT score   0.34   0.07
  <8 42.9±11.3 41.0±15.3
  8 or greater 45.5±12.7 35.0±13.8
Previous ‘heavy’ alcohol   0.35   0.06
  No 44.7±11.8 42.3±14.5
  Yes 42.5±11.6 36.6±15.2
IDU (ever)   0.92   0.005
  No 43.6±11.3 44.8±14.6
  Yes 43.9±12.0 36.1±14.2
IDU (current)   0.68   0.03
  No 43.9±11.8 40.1±14.8
  Yes 41.8±11.7 27.5±9.9
Current substance misuse   0.06   0.02
  No 45.2±10.8 41.3±14.7
  Yes 39.8±12.8 32.7±15.7
Moderate exercise   0.04   0.01
  No 41.7±11.6 36.4±14.6
  Yes 46.7±11.2 44.2±14.4
Vigorous exercise   0.006   0.02
  No 42.8±11.9 38.1±15.1
  Yes 49.9±7.7 47.9±12.1
Psychiatric disorder   0.035   <0.001
Continued
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Another important finding in this study was the overall 
high prevalence of reduced HRQoL in the cohort, with 
mean values for all domains of the SF36v2 being lower 
than the average for the US general population.23 This 
is probably due to a number of factors including the 
high prevalence of deprivation, mental health disorders, 
cirrhosis and the metabolic syndrome in the cohort. In 
this study, the presence of both cirrhosis and metabolic 
syndrome were independently associated with reduced 
overall physical health (PCS). Both of these factors have 
been shown to be associated with reduced HRQoL in 
other populations (both HCV and non- HCV).18 38 Factors 
independently associated with reduced overall mental 
health (MCS) in our cohort were a history of a mental 
health disorder and sedentary behaviour. A sedentary 
lifestyle and a history of a mental health disorder were 
also independently associated with lower scores in the 
hepatitis- specific scores: HD, PWB and HHD. We were 
not able to determine whether the association between 
engagement in regular moderate physical activity and 
better mental health was ‘cause’ or ‘effect’. The fact that 
we found associations between both presence of the meta-
bolic syndrome and history of a mental health disorder 
and reduced HRQoL and found a positive impact of 
physical activity on HRQoL suggests that engaging seden-
tary individuals with HCV in a physical activity/exercise 
programme may improve their general health. Formal 
assessment of a physical activity/exercise programme as 
a treatment strategy for reduced HRQoL in patients with 
HCV is worthy of a trial.
Our data illustrated that the presence of HCV viraemia 
was associated with reduced scores in the hepatitis- specific 
HRQoL domains; HLIM and HHD. Previous studies 
have shown that successful treatment of HCV infection 
is associated with reduced risk of liver- related complica-
tions, overall mortality, improved HRQoL, reduced risk 
of CV events and reduced incidence of T2DM, so treating 
HCV in infected individuals is a priority.15 16 However, as 
shown in the current study and others, despite successful 
clearance of HCV, the majority of individuals have 
comorbidity that persists, which may impact on health 
and well- being.19 20 With recent advances in antiviral 
treatment for HCV, nearly all patients can achieve SVR 
(cure) with a short course of DAAs.6 Given the simplicity 
of DAA treatment, patients with HCV now have far fewer 
clinical contacts with viral hepatitis teams than they did 
when treated with interferon- based treatment in the 
past. Moreover, many clinical teams are now focussing 
resources on trying to ‘eliminate’ HCV and are treating 
many more patients than previously.2 As a result, the care 
of individuals with HCV may have become less holistic. 
Given that we have demonstrated a high burden of 
potentially modifiable health problems in this cohort, 
this suggests we should incorporate more holistic care in 
our HCV treatment pathways. Care bundles have been 
shown to improve care in patients with liver disease in 
other settings.39 40 We therefore developed a clinical 
care bundle (figure 2) to address some non- HCV- related 
health problems. This bundle provides a checklist to 
ensure that patients are offered appropriate surveillance 
of cirrhosis- related complications; an assessment of CV 
risk; advice on smoking cessation, alcohol consumption 
and substance misuse; screening for depression and 
advice on physical activity and lifestyle in line with NICE 
guidelines. There is some evidence in the qualitative 
literature that treating HCV in infected individuals can 
be a ‘turning point’ in their lives, helping them focus on 
their general health.41 We hope that use of this bundle 
will help improve the general health and well- being of 
our patients. This bundle could be adapted for use in 
different settings specifically indicating who is responsible 
for managing specific aspects of the bundle (eg, primary 
care for initiating and monitoring the CV management 
and addiction services for managing substance/alcohol 
misuse). Formal evaluation of the impact of the care 
bundle is planned.
This study has some limitations. First, patients were 
recruited from hospital HCV clinics, which is likely to 
have a selection bias. A large proportion of our patients 
are now treated in community or prison clinics, so the 
prevalence of specific comorbidities addressed may be 
different in these settings. This cohort was older and had 
a higher prevalence of cirrhosis than patients seen our 
community outreach clinics.42 However, mental health 
disorders (up to 71%), excessive alcohol consumption 
(up to 29%) and other comorbidities were very preva-
lent in our community clinics, so patients are likely to 
benefit from a holistic, care bundle approach irrespec-
tive of their treatment setting. Second, the SF36v2 data 
were normalised to the US general population because 
UK data were not available to us. There may therefore be 
differences between the UK and US general populations 
Factor PCS P value MCS P value
  No 46.3±11.4 46.9±13.0
  Yes 41.4±11.5 32.9±13.5
Index of deprivation rs=0.21 0.04 rs=0.27 0.007
Bold values are statistically significant.
AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; HCV, hepatitis C virus; IDU, injecting drug used; MCS, mental 
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for the SF36v2 that we were unable to account for in this 
study. Third, this was a relatively small study with rela-
tively few HCV viraemic individuals limiting its power to 
assess some outcomes.
In conclusion, we have demonstrated that patients with 
HCV are at high risk of CV events, and potentially modi-
fiable risk factors are not being addressed adequately. In 
addition, HRQoL is reduced in all domains of the SF36v2 
compared with the general population, and this is asso-
ciated with the presence of cirrhosis, HCV viraemia, the 
metabolic syndrome, history of mental health disorder 
and sedentary behaviour. A care bundle has been devel-
oped with the aim of improving the general health and 
well- being of individuals with HCV.
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Table 3 Independent factors associated with unfavourable 
PCS, MCS and the hepatitis- specific HRQoL scores
PCS
Factor OR (95% CI) P value
Metabolic 
syndrome
3.5 (1.15 to 10.7) 0.027
Cirrhosis 3.7 (1.2 to 11.5) 0.022
MCS
Factor OR (95% CI) P value
Moderate 
exercise
0.14 (0.05 to 0.45) 0.001
Psychiatric 
disorder
8.6 (2.7 to 27.8) <0.001
Hepatitis Distress Scale
Factor aOR (95% CI) P value
Moderate 
exercise
17.52 (4.43 to 30.60) 0.009
Psychiatric 
disorder




−18.36 (−34.01 to −2.71) 0.022
Positive well- being
Factor aOR (95% CI) P value
Moderate 
exercise
15.27 (4.93 to 25.60) 0.004
Psychiatric 
disorder
−20.27 (−30.60 to −9.95) <0.001
Achieved SVR 9.98 (−1.16 to 21.13) 0.079
Hepatitis- specific Lmitation Scale
Factor aOR (95% CI) P value
Moderate 
exercise
11.77 (−2.17 to 25.71) 0.097
Metabolic 
Syndrome
−14.73 (−29.81 to 0.34) 0.055




−17.78 (−34.38 to −1.18) 0.036
Hepatitis- specific Distress Scale
Factor aOR (95% CI) P value
Moderate 
exercise
13.63 (0.07 to 27.19) 0.049
Psychiatric 
disorder
−23.03 (−36.80 to 9.25) 0.001
Achieved SVR 19.77 (5.12 to 34.41) 0.009
Corrected for gender and index of deprivation.
aOR, adjusted OR; HRQoL, health- related quality of life; MCS, 
mental health component summary; PCS, physical health 
component summary; SVR, sustained virological response.
Figure 2 Care bundle. AUDIT, Alcohol Use Disorders 
Identification Test; BMI, body mass index; BP, blood 
pressure; FRAX, fracture risk assessment tool; GAD7, 
General anxiety disorder 7; GP, general practitioner; HCC, 
hepatocellular carcinoma; N, no; N/A, not applicable; PHQ9, 
patient health questionaire - 9; T2DM, type 2 diabetes 
mellitus; Y, yes.
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